CTMC-drug discovery 2019 : CTMC--SCI(IF=3.374)--Recent advances in drug discovery and cancer diagnoses

In modern pharmaceutical companies, in-silico drug discovery has become a promising
solution for finding new drugs or detecting potential targets of preselected biomolecules. The process of drug discovery involves target identification, drug synthesis, virtual screening, and assays for therapeutic efficacy. Cancer is a major public health problem in the world. According to the recent survey from World Health Organization and International Agency for Research on Cancer, more than 18 million new cancer cases were diagnosed in the world in 2018. The results of tissue diagnosis, blood tests, computed tomography scans, cytogenetical analyses and etc. can provide informative clues about molecular changes and indicate proper prognoses. Particularly, timely detection of cancer significantly improves cancer outcomes by providing care at the earliest possible stage thus contributes greatly to the prevention of exacerbation and has become an important public health strategy in all settings. The main aim of this thematic issue is to collect and summarize the recent research of all aspects of drug design, virtual screening, drug discovery, cancer diagnosis, prognosis and treatment.